JP2021119123A - 目のピント調節改善用内服薬 - Google Patents
目のピント調節改善用内服薬 Download PDFInfo
- Publication number
- JP2021119123A JP2021119123A JP2020093419A JP2020093419A JP2021119123A JP 2021119123 A JP2021119123 A JP 2021119123A JP 2020093419 A JP2020093419 A JP 2020093419A JP 2020093419 A JP2020093419 A JP 2020093419A JP 2021119123 A JP2021119123 A JP 2021119123A
- Authority
- JP
- Japan
- Prior art keywords
- keishikaryukotsuboi
- extract
- weight
- accommodation
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 31
- 230000004308 accommodation Effects 0.000 claims description 26
- 238000002360 preparation method Methods 0.000 claims description 6
- 201000010041 presbyopia Diseases 0.000 claims description 5
- 238000004904 shortening Methods 0.000 abstract description 2
- 239000000284 extract Substances 0.000 description 27
- 239000000843 powder Substances 0.000 description 16
- 239000000654 additive Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 235000012054 meals Nutrition 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000001035 drying Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 210000000695 crystalline len Anatomy 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 229940126701 oral medication Drugs 0.000 description 3
- 229940124595 oriental medicine Drugs 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- -1 brighteners Substances 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000000422 nocturnal effect Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical class CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940124568 digestive agent Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000009382 keishi-to Substances 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
項1. 桂枝加竜骨牡蛎湯エキスを含有する、目のピント調節改善用内服薬。
項2. 前記目のピント調節改善が、調節緊張時間及び/又は調節緩和時間の短縮である、項1に記載の内服薬。
項3. 老眼に適用される、項1又は2に記載の内服薬。
桂枝加竜骨牡蛎湯の漢方処方としては、「新 一般用漢方処方の手引き」(合田 幸広・袴塚 高志監修、日本漢方生薬製剤協会編集、株式会社じほう発行)に記載されている漢方処方が好ましく、具体的には、ケイヒ、シャクヤク、タイソウ、リュウコツ、ボレイ、カンゾウ、及びショウキョウからなる混合生薬が挙げられる。また、桂枝加竜骨牡蛎湯には、漢方生薬調査会により定められた「漢方製剤の基本的取扱い方針」に規定されるように、現在繁用されている漢方関係の書簡に記載されている混合生薬(漢方処方)が包含される。
本発明の内服薬は、桂枝加竜骨牡蛎湯エキス単独からなるものであってもよく、製剤形態に応じた添加剤や基剤を含んでいてもよい。このような添加剤及び基剤としては、薬学的に許容されることを限度として特に制限されないが、例えば、賦形剤、結合剤、崩壊剤、滑沢剤、等張化剤、可塑剤、分散剤、乳化剤、溶解補助剤、湿潤化剤、安定化剤、懸濁化剤、粘着剤、コーティング剤、光沢化剤、水、油脂類、ロウ類、炭化水素類、脂肪酸類、高級アルコール類、エステル類、水溶性高分子、界面活性剤、金属石鹸、低級アルコール類、多価アルコール、pH調整剤、緩衝剤、酸化防止剤、紫外線防止剤、防腐剤、矯味剤、香料、粉体、増粘剤、色素、キレート剤等が挙げられる。これらの添加剤は、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。また、これらの添加剤及び基剤の含有量については、使用する添加剤及び基剤の種類、内服薬の製剤形態等に応じて適宜設定される。
本発明の内服薬の製剤形態については、経口投与が可能であることを限度として特に制限されないが、例えば、散剤、細粒剤、顆粒剤(ドライシロップを含む)、錠剤、丸剤、カプセル剤(軟カプセル剤、硬カプセル剤)等の固形状製剤;ゼリー剤等の半固形状製剤;液剤、懸濁剤、シロップ剤等の液状製剤が挙げられる。これらの製剤形態の中でも、含有成分の安定性や携帯性等の観点から、好ましくは固形状製剤が挙げられる。
本発明の内服薬は、目のピント調節の改善を目的として用いられる。より具体的には、本発明の内服薬は、調節緊張時間及び/又は調節緩和時間を短縮することを目的として用いられる。
本発明の内服薬は経口投与によって使用される。本発明の内服薬の用量については、投与対象者の年齢、性別、体質、症状の程度等に応じて適宜設定されるが、例えば、ヒト1人に対して1日当たり、桂枝加竜骨牡蛎湯エキスの乾燥エキス末量換算で0.2〜20g程度、好ましくは0.5〜10g程度、より好ましくは1〜5g程度、さらに好ましくは1.5〜3g程度となる量で、1日1〜3回、好ましくは2又は3回の頻度で服用すればよい。服用タイミングについては、特に制限されず、食前、食後、又は食間のいずれであってもよいが、食前(食事の30分前)又は食間(食後2時間後)が好ましい。
原料生薬を、ケイヒ2重量部、シャクヤク2重量部、タイソウ2重量部、リュウコツ1.5重量部、ボレイ1.5重量、カンゾウ1重量部、及びショウキョウ0.5重量部の割合で用い、これらを刻んだ後、水20倍重量(210重量部)を用いて約100℃で1時間抽出し、遠心分離して抽出液を得、減圧下で濃縮してスプレードライヤーを用いて乾燥し、桂枝加竜骨牡蛎湯エキス末を得た。得られた桂枝加竜骨牡蛎湯エキス末は、原料生薬混合物105g当たり25gであった。なお、スプレードライヤーによる乾燥は、抽出液を回転数10000rpmのアトマイザーに落下させ、150℃の空気の熱風を供給して行った。
老視を自覚する9名(39〜51歳)に、桂枝加竜骨牡蛎湯エキス末を、1日当たり2.3g(乾燥エキス量換算、2回に分けて食前または食間に服用)を2週間服用させた。
Claims (3)
- 桂枝加竜骨牡蛎湯エキスを含有する、目のピント調節改善用内服薬。
- 前記目のピント調節改善が、調節緊張時間及び/又は調節緩和時間の短縮である、請求項1に記載の内服薬。
- 老眼に適用される、請求項1又は2に記載の内服薬。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020093419A JP2021119123A (ja) | 2020-05-28 | 2020-05-28 | 目のピント調節改善用内服薬 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020093419A JP2021119123A (ja) | 2020-05-28 | 2020-05-28 | 目のピント調節改善用内服薬 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021119123A true JP2021119123A (ja) | 2021-08-12 |
Family
ID=77195346
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020093419A Pending JP2021119123A (ja) | 2020-05-28 | 2020-05-28 | 目のピント調節改善用内服薬 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2021119123A (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7500278B2 (ja) | 2020-05-28 | 2024-06-17 | 小林製薬株式会社 | 瞳孔調節機能の改善用内服薬 |
-
2020
- 2020-05-28 JP JP2020093419A patent/JP2021119123A/ja active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7500278B2 (ja) | 2020-05-28 | 2024-06-17 | 小林製薬株式会社 | 瞳孔調節機能の改善用内服薬 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7968128B2 (en) | Plant extract compositions for affecting sleep | |
EP1763359B1 (en) | Use of pregnane glycosides in the treatment/management of obesity | |
WO2009079601A1 (en) | Methods and systems for sublingual guarana administration | |
CN1853682A (zh) | 用于改善睡眠持续时间和质量的基于植物的食品强化剂 | |
Yampolsky et al. | Sea buckthorn (lat. Hippophaë) | |
US11426439B2 (en) | Nutritional product and method of using it | |
KR20240004452A (ko) | 1-메틸크산틴-기반 생체활성 조성물 및 이의 사용 방법 | |
JP2021119123A (ja) | 目のピント調節改善用内服薬 | |
KR101987418B1 (ko) | 혼합 생약 추출물을 유효성분으로 함유하는 뇌신경 보호용 조성물 | |
JP2019054791A (ja) | 疲労改善用組成物 | |
JP7500278B2 (ja) | 瞳孔調節機能の改善用内服薬 | |
JP6935285B2 (ja) | 医薬組成物 | |
JP7385990B2 (ja) | 過眠症治療剤 | |
JP2020169123A (ja) | ホットフラッシュ改善剤 | |
JP2022022617A (ja) | 筋肉合成能促進剤 | |
US10933109B2 (en) | Compositions and methods for sleep disorders and restless leg syndromes | |
JP7068803B2 (ja) | 血中脂質低減用医薬組成物 | |
JP7409938B2 (ja) | 月経前の食欲亢進抑制剤 | |
JP2023145935A (ja) | 沢瀉湯エキス製剤 | |
JP2021119125A (ja) | 食欲調整ホルモン分泌正常化剤 | |
JP2024017060A (ja) | Tie2活性化剤 | |
JP2017529314A (ja) | 冷え症等の全身症状改善用経口組成物 | |
JP2023055578A (ja) | デジタル不調改善薬 | |
JP2024031740A (ja) | 夕方不調改善薬 | |
JP2024017078A (ja) | 筋肉水分量改善剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200720 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200720 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221222 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231121 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231122 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240514 |